Mazdutide vs Tirzepatide
Two dual-receptor GLP-1 peptides, two different second targets. Tirzepatide pairs GLP-1 with GIP; Mazdutide pairs GLP-1 with glucagon receptor (GCGR) agonism. This comparison covers mechanisms, trial data, and which mechanism fits which research question.
Mazdutide
Dual GLP-1/GCGR co-agonist. Glucagon component adds hepatic fat oxidation and thermogenesis to standard GLP-1 appetite suppression.
Shop Mazdutide →Tirzepatide
Dual GLP-1/GIP agonist. GIP component enhances insulin secretion and produces the largest published weight-loss dataset of any dual agonist.
Shop Tirzepatide →Side-by-Side Comparison
| Factor | Mazdutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1 + Glucagon (GCGR) | GLP-1 + GIP |
| Developer | Innovent Biologics (IBI362) | Eli Lilly |
| Secondary mechanism benefit | Hepatic fat oxidation, thermogenesis | Enhanced insulin secretion, appetite suppression |
| Dosing frequency | Once weekly | Once weekly |
| Regulatory status | Phase 3 (GLORY trials), approved in China for some indications | FDA-approved (Mounjaro/Zepbound) |
| Published dataset size | Smaller, primarily Chinese population trials | Large, global SURMOUNT/SURPASS trial program |
| Best for | Comparative research on GCGR-driven thermogenesis | Best-characterised dual agonist for weight/glucose research |
Mechanism Deep Dive
Mazdutide — GLP-1 + Glucagon
Mazdutide layers glucagon receptor agonism onto a GLP-1 backbone. While GLP-1 signalling suppresses appetite and improves glucose handling, glucagon receptor activation independently increases hepatic glucose output and thermogenesis — a mechanism more similar to Retatrutide's third receptor than to Tirzepatide's GIP pathway. Phase 2/3 GLORY trial data shows meaningful weight reduction and glycaemic improvement.
Shop Mazdutide →Tirzepatide — GLP-1 + GIP
Tirzepatide's GIP receptor co-agonism potentiates GLP-1 signalling synergistically rather than additively, producing stronger appetite suppression and superior lean mass preservation. Its SURMOUNT trial program is the most extensive dual-agonist dataset available, showing up to 22.5% weight reduction at 72 weeks.
Shop Tirzepatide →Which Peptide Wins For Each Goal?
Best-characterised weight loss data
Tirzepatide
SURMOUNT-1 through 4 provide the largest, most replicated dataset of any dual-agonist peptide.
Researching glucagon-driven thermogenesis
Mazdutide
GCGR agonism is mechanistically distinct from GIP — useful for comparative energy-expenditure research alongside Retatrutide.
Glycaemic control research
Tirzepatide
GIP co-agonism produces well-documented insulin-secretion enhancement in SURPASS trial data.
Comparative dual-agonist mechanism studies
Both
Running Mazdutide and Tirzepatide in parallel research protocols isolates GIP-driven vs glucagon-driven effects on the same GLP-1 backbone.
Frequently Asked Questions
What is the difference between Mazdutide and Tirzepatide?
Both are dual-receptor agonists built on a GLP-1 backbone, but their second target differs. Tirzepatide adds GIP receptor agonism, enhancing insulin secretion and appetite suppression. Mazdutide adds glucagon receptor (GCGR) agonism, driving hepatic fat oxidation and thermogenesis instead.
Which produces more weight loss, Mazdutide or Tirzepatide?
Tirzepatide has the larger dataset — Phase 3 SURMOUNT trials showed up to 22.5% weight loss at 72 weeks. Mazdutide's Phase 3 GLORY trial data (conducted primarily in Chinese populations) shows meaningful weight loss and glycaemic improvement, though with a smaller published dataset than Tirzepatide to date.
Is Mazdutide FDA-approved?
No. Mazdutide (IBI362) is developed by Innovent Biologics and is further along in regulatory review in China than in North America. Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss).
Research use only. All products sold by JA Performance are strictly for laboratory and in vitro research purposes. Not for human consumption, medical use, or veterinary use.